November 19, 2019 8:36am
The real question is whether it’s an investor oriented sector or just a trading opportunity?
If the Cell &Gene Therapy sector runs out of buyers, it runs into trouble (just like a fire that runs out of wood).
Another question, which companies have drawn the “short straws” in the race for financing?
MY pre-open indications: SELL - CLBS, CRSP, RENE.L SGMO, STML and ALNY; BUY – SAGE and AXGN
My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline – which are?
Dow futures are UP +0.14% (+40 points), S&P futures are UP +0.22% (+7 points) and NASDAQ futures are UP +0.39% (+33 points)
U.S. stock index futures were slightly higher on Tuesday morning;
European markets opened positive despite uncertainty and pessimism over the outcome of trade talks between the U.S. and China while the pan-European Stoxx 600 climbed +0.75% by mid-morning to hit its highest since May 2015;
Asia Pacific stocks were mixed amid concerns over the state of U.S.-China trade negotiations.
Data Docket: a reading on housing starts is expected out at 8:30 a.m. ET.
We should be looking for a reverse of yesterday’s downward slide in our sector.
Although tax selling season is coming early!!
Monday night’s newsletter heading: “resilience is not in the sector’s vocabulary.”
- The NASDAQ closed UP +9.11 points (+0.11%);
- The IBB closed down -0.26% and the XBI closed up +0.24%;
- The close was negative with an A/D line of 18/22, 2 flats, 1 reversed merged (HSGX) and 2 acquired;
- 8 out of the 18 upside had higher than the 3 month average volume;
- 5 out of the 22 downside had higher than the 3 month average volume;
Review the context of Q4’s market – so far:
- November has registered 5 positive and 7 negative close;
- October registered 10 positive, 1 neutral and 14 negative closes;
Companies in my headlights – It’s your decision; I provide an idea and context:
SELL into strength and news: CLBS, CRSP, RENE.L SGMO, STML and ALNY – depending on entry pricing
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.